FDA rewrites drug approval rules and longevity stands to gain
FDA leaders signaled that a single well-controlled pivotal trial will generally suffice for drug approval, replacing the longstanding two-trial expectation. The policy lowers development costs and timelines, increases the viability of biomarker-driven and postmarketing strategies for aging-focused therapies, and shifts risk onto developers and regulators balancing evidence versus access.
Why it mattersFDA's shift to one pivotal trial lets investors reallocate R&D budgets toward biomarker-driven, phase III-sized longevity studies.